A Phase II, randomized, open-label, multicenter, clinical study to evaluate the safety and efficacy of lenvatinib monotherapy E7080/MK-7902 and pembrolizumab MK- 3475 plus lenvatinib combination therapy in participants with recurrent or metastatic head and neck squamous cell carcinoma R/M HNSCC who progress after immunotherapy PD-1/PD-L1 inhibitors

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04428151

Study #:
STUDY00145942

Start Date:
Jan 05, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04428151

View Complete Trial Details & Eligibility at ClinicalTrials.gov